vTv Therapeutics, Inc. Class A Stock price
Is vTv Therapeutics, Inc. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.
Key metrics
vTv Therapeutics, Inc. Class A Stock Analysis
Analyst Opinions
11 Analysts have issued a vTv Therapeutics, Inc. Class A forecast:
Analyst Opinions
11 Analysts have issued a vTv Therapeutics, Inc. Class A forecast:
Don't miss a Thing! We will send you all news about vTv Therapeutics, Inc. Class A directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
vTv Therapeutics, Inc. Class A Stock News
Company Profile
vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.
| Head office | United States |
| CEO | Mr. Sekhri |
| Employees | 26 |
| Founded | 2015 |
| Website | vtvtherapeutics.com |


